Eric Poma
Vorstandsvorsitzender bei MOLECULAR TEMPLATES, INC.
Vermögen: 29 611 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Eric Poma
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 26 | |
Molecular Templates OpCo, Inc.
 Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.
6
| Subsidiary | Financial Conglomerates | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Eric Poma
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| CURIS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Napo Pharmaceuticals, Inc.
 Napo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Napo Pharmaceuticals, Inc. provides pharmaceutical products for gastro-intestinal disorders. The company was founded by Lisa A. Conte in November 2001 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | President | |
Seaview Securities LLC
 Seaview Securities LLC Investment Banks/BrokersFinance Seaview Securities LLC provides investment banking services focused on the life sciences industry. The firm's services include private placements, mergers & acquisitions, financial and business strategy advisory, and underwriting services. The company was founded in January 2002 by Russell L. Pollack and Joseph P. Dougherty and is headquartered in New York, NY. | Investment Banks/Brokers | Founder | |
| CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| IMMUNOME, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Brown University | College/University | Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree Undergraduate Degree | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | General Counsel | |
| University of Oxford | College/University | Doctorate Degree | |
Fish & Neave LLP
 Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Fish & Neave operates as a law firm. It specializes in specializes in intellectual property issues involving patents, trademarks, and copyrights. The company is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Texas A&M University | College/University | Undergraduate Degree | |
| University of Alberta | College/University | Doctorate Degree | |
| The University of Arkansas | College/University | Doctorate Degree | |
| New York University | College/University | Graduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree | |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Biotechnology | Director/Board Member | |
St. Jude Children's Research Hospital, Inc.
 St. Jude Children's Research Hospital, Inc. Hospital/Nursing ManagementHealth Services St. Jude Children's Research Hospital, Inc. offers health care and social assistance services for children. It is internationally recognized for its pioneering research and treatment for children with cancer and other catastrophic diseases. The firm's treatment programs include brain tumors, leukemia, lymphoma, infectious diseases, immunodeficiency diseases, blood disorders, sickle cell disease, and solid tumors. The company was founded by Danny Thomas on February 4, 1962 and is headquartered in Memphis, TN. | Hospital/Nursing Management | Director/Board Member | |
| Hospital for Sick Children Foundation | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| Princess Margaret Hospital Foundation | Corporate Officer/Principal | ||
| Lehman Brothers, Inc. /Istanbul Division/ | Investment Managers | Corporate Officer/Principal | |
| Weill Cornell Medical College | College/University | Corporate Officer/Principal | |
| Ontario Cancer Institute | Chief Tech/Sci/R&D Officer | ||
Caxton Alternative Management LP
 Caxton Alternative Management LP Investment ManagersFinance Caxton Alternative Management LP (do-business-as CAM Capital) is a single-family office which was founded in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Headquartered in New York City, CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. | Investment Managers | Chief Executive Officer | |
Ropes & Gray LLP
 Ropes & Gray LLP Miscellaneous Commercial ServicesCommercial Services Ropes & Gray LLP provides legal and private equity services. Its practice areas include asset management, banking, business and commercial litigation, business restructuring, capital markets and corporate governance and compliance. The company was founded in 1865 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Valence Life Sciences LLC
 Valence Life Sciences LLC Investment ManagersFinance Valence Life Sciences LLC (Valence Life Sciences) is an venture capital firm founded in 2012 by Rachel Anne Leheny and Eric Wayne Roberts. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Doctorate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| Fordham University School of Law | College/University | Graduate Degree | |
| Columbia Business School | College/University | Masters Business Admin | |
| University of Vermont College of Medicine | College/University | Doctorate Degree | |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BA Ruskin Law, LLC | President | ||
| JAGUAR HEALTH, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Palvella Therapeutics, Inc.
 Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Biotechnology | Director/Board Member | |
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| VIRPAX PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Antios Therapeutics, Inc.
 Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Director/Board Member | |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Biotechnology | Director of Finance/CFO Chief Executive Officer | |
| Burke Neurological Institute | Director/Board Member | ||
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 43 |
| Kanada | 5 |
| Vereinigtes Königreich | 3 |
| Türkei | 2 |
| Norwegen | 2 |
Sektoral
| Health Technology | 21 |
| Consumer Services | 16 |
| Finance | 6 |
| Commercial Services | 5 |
| Health Services | 2 |
Operativ
| Director/Board Member | 76 |
| Corporate Officer/Principal | 50 |
| Independent Dir/Board Member | 27 |
| Chief Tech/Sci/R&D Officer | 22 |
| Undergraduate Degree | 20 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Harold Selick | 24 |
| Kevin Lalande | 24 |
| David Hirsch | 20 |
| Scott Morenstein | 17 |
| Adam Daniel Cutler | 16 |
| Corazon Sanders | 12 |
| Barbara A. Ruskin | 12 |
| David Hoffmann | 10 |
| Conrad Jordaan | 10 |
| Roger Waltzman | 10 |
| Jonathan Lanfear | 9 |
| Jason Kim | 9 |
| Nenad Sarapa | 8 |
| Gabriela Gruia | 8 |
| Jack Higgins | 6 |
